HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arden Scoops Up Christina Aguilera License From P&G

This article was originally published in The Rose Sheet

Executive Summary

Previously intended for Coty under its merger deal with P&G, the Christina Aguilera fragrance license increases Elizabeth Arden's exposure to the vagaries of the celebrity-scent market, but could offer a boost to its European business. The firm reported growing sales in the third quarter, excluding currency effects, as its turnaround progresses.

You may also be interested in...

Revlon Targets Prestige Channel, Fragrance Growth With Elizabeth Arden Buy

Firm’s $870m acquisition of Elizabeth Arden is seen as “highly complementary,” bringing prestige skin care and scalable fragrance licenses to its existing business focused on mass and salon beauty and hair care. The deal also offers synergies and cost-reduction opportunities for both companies, which have struggled in recent years to rejuvenate their businesses.

Inside The Coty/P&G Beauty Mega Deal

Coty faced off against 44 other interested parties last year to eventually win P&G's beauty business with its $12.5bn merger bid, ushering it to the top tier of the global beauty industry. An April 22 SEC filing offers inside details on Coty and P&G's businesses and how the deal came together.

In Brief: Revlon Sale?; P&G/Coty Fragrance Transfer; More

SEC filing affirms Revlon is exploring strategic alternatives; Procter & Gamble will transfer 10 fragrance licenses to Coty. More news in brief.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts